About the Company
We do not have any company description for Vaxcyte, Inc. at the moment.
Exchange
Nasdaq
Fundamental Data and Insider Transactions (Quarterly data) Full Screen
Loading the fundamentals chart...
Latest News on Vaxcyte, Inc.
Why Vaxcyte, Inc. (PCVX) Is One of the Best Vaccine Stocks to Buy ...
Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage vaccine innovation company that develops high-fidelity vaccines. It continues to develop broad-spectrum conjugate and novel protein vaccines to ...
Vaxcyte, Inc. Navigates AI Risks Amidst Regulatory and Ethical ...
Vaxcyte, Inc. faces significant risks associated with its incorporation of artificial intelligence (AI) into its operations, as these technologies present technical complexities, potential data ...
Vaxcyte’s stock soars after trial shows positive data for ...
Vaxcyte Inc.’s stock soared 42% Tuesday, after the vaccine maker reported positive results from an early-stage trial of its 31-valent pneumococcal conjugate vaccine candidate in adults aged 50 ...
Decoding Vaxcyte Inc (PCVX): A Strategic SWOT Insight
Vaxcyte Inc's financial overview for the nine months ended September 30, 2024, reveals a significant investment in research and development, totaling $343.03 million, up from $228.19 million in ...
Vaxcyte Reports Progress and Strengthens Financial Position
Vaxcyte, Inc. is a clinical-stage vaccine innovation company that focuses on developing high-fidelity vaccines for bacterial diseases, with a primary focus on broad-spectrum pneumococcal conjugate ...
Vaxcyte's stock soars 42% to record high after trial shows positive ...
Vaxcyte Inc.'s stock soared 42% Tuesday to a record high above $115, after the vaccine maker reported positive results from an early-stage trial of its 31-valent pneumococcal conjugate vaccine ...
Vaxcyte, Inc. to Announce Q4 and Full Year 2024 Financial ... - Nasdaq
Vaxcyte, Inc., a clinical-stage vaccine innovation company, announced it will release its financial results for the fourth quarter and full year 2024 on February 25, 2025, after market close.
Why Vaxcyte, Inc. (PCVX) Is Among the Best Healthcare Stocks To Buy ...
Vaxcyte, Inc. (NASDAQ:PCVX) is a clinical-stage biotechnology vaccine company, engaged in developing novel protein vaccines to prevent or treat bacterial infectious diseases.
Is Vaxcyte, Inc. (PCVX) the Best Up and Coming Stock to Buy According ...
Vaxcyte, Inc. (NASDAQ:PCVX) is advancing VAX-31 into a Phase 3 program for adults, with initiation expected by mid-2025 and top-line data anticipated in 2026.
Vaxcyte's stock rallies 46% on positive data for its pneumococcal ...
Shares of Vaxcyte Inc. soared 46.7% in premarket trading on Monday after the company said its experimental 24-valent pneumococcal conjugate vaccine met the primary endpoint in a Phase 1/2 clinical ...
Similar Companies
Loading the latest forecasts...